Pink Sheet Podcast: Pfizer Pulls Sickle Cell Drug, ODAC Calls Back Approved Products, New AAM CEO

 
• By Pink Sheet Team

Pink Sheet reporters and editors discuss Pfizer’s abrupt decision to withdraw Oxbryta, the US FDA’s Oncologic Drugs Advisory Committee bringing sponsors of approved products back to discuss labeling changes while competitors are pending, and the new CEO of a generic industry trade association.

Pink Sheet podcast
Will more sponsors see advisory committees consider labeling changes for approved products along with their pending competitors? • Source: Citeline/Shutterstock

More from US FDA Performance Tracker

More from US Advisory Committees